 |
|
|
| Antibiotic / Antimicrobial Resistance |
|
|
| Home > Clinical Guidelines |
|
Clinical Guidelines
| Healthcare-Associated Infections |
 |
Recommendations for Preventing the Spread of Vancomycin Resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC)
Morbidity and Mortality Weekly Report (MMWR). September 22, 1995;44(RR12):1-13.
(Also available in PDF format [212 KB, 20 pages].) |
|
Interim Guidelines for Prevention and Control of Staphylococcal Infection Associated with Reduced Susceptibility to Vancomycin
Morbidity and Mortality Weekly Report (MMWR). July 11, 1997;46(27):626-628, 635.
(Also available in PDF format [246 KB, 20 pages].) |
|
Guidelines and Recommendations for Hospital-Related Infections |
| Malaria |
|
Availability and Use of Parenteral Quinidine Gluconate for Severe or Complicated Malaria
Since 1991, quinidine gluconate, a class 1a anti-arrhythmic agent, has been the only parenteral antimalarial available for use in the United States. It is indicated for the treatment of patients with life-threatening Plasmodium falciparum malaria, including those who cannot tolerate oral therapy, have high-grade parasitemia, or have complications (e.g., cerebral malaria or acute renal failure). The limited availability of and delays in obtaining quinidine gluconate have contributed to adverse patient outcomes. As newer anti-arrhythmics have replaced quinidine for many cardiac indications, some hospitals and other health-care facilities have dropped quinidine gluconate from their formularies and, as a result, fewer clinicians have had experience using the drug. Discussions among quinidine gluconate manufacturer Eli Lilly Company (Indianapolis, Indiana), CDC, the U.S. Department of Defense, and the U.S. Food and Drug Administration have resulted in the following recommendations to improve quinidine gluconate availability for acutely ill malaria patients in U.S. health-care facilities.
Morbidity and Mortality Weekly Report (MMWR). December 22, 2000;49(50):1138-1140.
(Also available in PDF format [200 KB, 24 pages].) |
|
Information for Health Care Providers: MalaroneT for Malaria Treatment and Prophylaxis (October 27, 2000)
MalaroneT (a fixed combination of atovaquone and proguanil hydrochloride) is a new antimalarial drug approved in the United States in July 2000 for both treatment and prophylaxis of malaria. Malarone has been shown to be highly efficacious in the treatment of uncomplicated malaria caused by Plasmodium falciparum, including malaria that has been acquired in areas with chloroquine-resistant or multidrug-resistant strains. |
| Sexually Transmitted Diseases |
|
Sexually Transmitted Diseases Treatment Guidelines 2006 |
| Tuberculosis |
|
Fact Sheet: Treatment of Drug-Resistant Tuberculosis |
|
Management of Persons Exposed to Multidrug-Resistant Tuberculosis
Morbidity and Mortality Weekly Report (MMWR). June 19, 1992;41(RR-11):59-71. |
| Upper Respiratory Tract Infections |
|
Principles for Appropriate Antibiotic Use  |
| |
 |
Principles of Appropriate Antibiotic Use for Treatment of Acute Respiratory Tract Infections in Adults: Background, Specific Aims, and Methods
Gonzales R, Bartlett JG, Besser RE, Cooper RJ, Hickner JM, Hoffman JR, Sande MA. Annals of Internal Medicine. March 20, 2001;134:479-486.
The guidelines in this issue provide evidence-based recommendations for evaluation and treatment of adults with acute respiratory illnesses. This paper describes the background and specific aims of and methods used to develop these principles. The goal of the principles is to provide clinicians with practical strategies for limiting antibiotic use to the patients who are most likely to benefit from it.
(Also available in PDF format [178 KB, 8 pages].) |
|
Principles of Appropriate Antibiotic Use for Treatment of Nonspecific Upper Respiratory Tract Infections in Adults: Background
Gonzales R, Bartlett JG, Besser RE, Hickner JM, Hoffman JR, Sande MA. Annals of Internal Medicine. March 20, 2001;134:490-494.
The goals of this paper are to provide evidence-based recommendations for when to apply the diagnosis of upper respiratory tract infection and when to consider antibiotic treatment of adults with an uncomplicated upper respiratory tract infection.
(Also available in PDF format [145 KB, 5 pages].) |
|
Principles of Appropriate Antibiotic Use for Acute Rhinosinusitis in Adults: Background
Hickner JM, Bartlett JG, Besser RE, Gonzales R, Hoffman JR, Sande MA. Annals of Internal Medicine. March 20, 2001;134:498-505.
This paper argues for a conservative approach to use of antibiotics in patients with sinusitis-like symptoms, consistent with efforts to reduce antibiotic use for respiratory infections in ambulatory patients.
(Also available in PDF format [180 KB, 8 pages].) |
|
Principles of Appropriate Antibiotic Use for Acute Pharyngitis in Adults: Background
Cooper RJ, Hoffman JR, Bartlett JG, Besser RE, Gonzales R, Hickner JM, Sande MA. Annals of Internal Medicine. March 20, 2001;134:509-517.
Most immunocompetent adults with sore throat have acute infectious pharyngitis. Widespread antibiotic use in such patients has been based on an effort to treat bacterial (particularly streptococcal) pharyngitis. This paper addresses the rational treatment of nongonococcal, nondiphtherial acute pharyngitis in healthy adults.
(Also available in PDF format [189 KB, 9 pages].) |
|
Principles of Appropriate Antibiotic Use for Treatment of Uncomplicated Acute Bronchitis: Background
Gonzales R, Bartlett JG, Besser RE, Cooper RJ, Hickner JM, Hoffman JR, Sande MA. Annals of Internal Medicine. March 20, 2001;134:521-529.
Most cases of acute bronchitis occur in otherwise healthy adults, in whom this acute cough illness can be called "uncomplicated acute bronchitis." This paper discusses use of antibiotics in these patients.
(Also available in PDF format [187 KB, 9 pages].) |
| Sources for Guidelines |
|
NCID Infectious Disease Guidelines
Links to professional guidelines published by NCID for the prevention, treatment, surveillance, and control of infectious diseases. |
|
CDC Prevention Guidelines Database
A comprehensive compendium of all of the official guidelines and recommendations published by CDC for the prevention of diseases, injuries, and disabilities. |
|
National Guideline Clearinghouse™
A public resource for evidence-based clinical practice guidelines. NGC is sponsored by the Agency for Healthcare Research and Quality (AHRQ). |
|
Note: These sites are not CDC sites and will be opened in a new browser window. CDC is not
responsible for the content of Web pages found at these links. Links to nonfederal organizations
are provided solely as a service to our users. These links do not indicate an endorsement of these
organizations by CDC or the federal government. |
|
| |
| |
Date: September 14, 2006
Content source: National Center for Infectious Diseases/Division of Bacterial and Mycotic Diseases |
|
